January 7, 2020
Beginning this month, Hyogo College of Medicine Hospital, one of Japan’s leading medical institutions in the field of inflammatory bowel disease (IBD), started to switch from the TNFα inhibitor Remicade (infliximab) to its biosimilars. IBD is said to be an...read more